The Alexander Shulgin Research Institute (ASRI) is a psychedelics discovery, development, and educational organization dedicated to continuing and extending the work of Dr. Alexander “Sasha” Shulgin. It focuses on design, chemical synthesis, and pharmacological evaluation of novel compounds as well as characterization of hundreds of compounds from the Shulgin Vault. ASRI has synthesized and supplied compounds for basic chemical, pharmacological, and clinical studies at universities and research organizations worldwide, and has supported recent FDA‑approved clinical research with psilocybin and DMT. The institute was informally founded by Dr. Shulgin in the 1980s and was formally incorporated on April 19, 2021; Paul F. Daley, Ph.D., and Nicholas V. Cozzi, Ph.D. lead the organization. The company emphasizes scientific excellence, high ethical standards, and education, and the Seed financing is intended to support establishment of a modern Shulgin Research Laboratory. The press release lists Toronto, ON as the release location.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2021